Skip to main content

Abnormal DNA Repair clinical trials at UC Davis
1 research study open to eligible people

  • A Study of the Experimental Medicine Olaparib For Advanced Urothelial Cancer With DNA-Repair Defects

    open to eligible people ages 18 years and up

    This phase II trial studies how well olaparib works in treating patients with urothelial cancer with DNA-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Sacramento, California and other locations

Last updated: